KSQ-4279, a first-in-class USP1 inhibitor shows strong combination activity in BRCA mutant cancers with intrinsic or acquired resistance to PARP inhibitors

Autor: L. Cadzow, P.C. Gokhale, S. Ganapathy, P. Sullivan, S. Nayak, S. Shenker, M. Schlabach, E. Tobin, U.A. Matulonis, J.F. Liu, F. Stegmeier, A. Wylie

Publikováno v: European Journal of Cancer. 174:S37-S38

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::25672c349ddceabb9916216314647448
https://doi.org/10.1016/s0959-8049(22)00900-5

USP1 inhibitors show robust combination activity and a distinct resistance profile from PARP inhibitors

Autor: L. Cadzow, M. McGuire, M. Schlabach, Andrew Wylie, G. Histen, S. Shenker, P. Grasberger, E. Chipumuro, R. Rahal, E. Tobin, P. Sullivan, N. Hafeez, K. Sinkevicius, F. Stegmeier

Publikováno v: European Journal of Cancer. 138:S7-S8

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f360dff0542e044dc900ced2af08bac8
https://doi.org/10.1016/s0959-8049(20)31087-x

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Pan-cancer Analysis of Homologous Recombination Deficiency in Cell Lines.

Autor: Dodson AE; KSQ Therapeutics, Lexington, MA, United States., Shenker S; KSQ Therapeutics, Lexington, MA, United States., Sullivan P; KSQ Therapeutics, Lexington, MA, United States., Nayak SU; KSQ Therapeutics, Lexington, MA, United States., Middleton C; KSQ Therapeutics, Lexington, MA, United States., McGuire M; KSQ Therapeutics, Lexington, MA, United States., Chipumuro E; Dicerna Pharmaceuticals, Inc, Cambridge, MA, United States., Mishina Y; KSQ Therapeutics, Lexington, MA, United States., Tobin ER; KSQ Therapeutics, Lexington, MA, United States., Cadzow L; KSQ Therapeutics, Lexington, MA, United States., Wylie AA; KSQ Therapeutics, Lexington, MA, United States., Sangurdekar D; KSQ Therapeutics, Lexington, MA, United States.

Publikováno v: Cancer research communications [Cancer Res Commun] 2024 Nov 01. Date of Electronic Publication: 2024 Nov 01.